Pancreatic Ductal Adenocarcinoma (PDAC) – Market Access and Reimbursement Insights Report – 2025

Pancreatic Ductal Adenocarcinoma (PDAC) Market Access and Reimbursement Insights

Thelansis’s “Pancreatic Ductal Adenocarcinoma (PDAC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Pancreatic Ductal Adenocarcinoma (PDAC) Overview

Pancreatic Ductal Adenocarcinoma (PDAC) is the most prevalent and lethal form of pancreatic cancer, characterized by originating in the exocrine duct cells and having an exceptionally poor prognosis due to its typically asymptomatic early stages and late diagnosis in locally advanced or metastatic phases. Biologically, PDAC is driven by near-universal mutations in the KRAS oncogene, coupled with frequent inactivation of tumor suppressors like CDKN2A, TP53, and SMAD4. A hallmark challenge is the extensive, dense, and immune-suppressive desmoplastic tumor microenvironment (TME) that creates a physical barrier limiting drug delivery. Diagnosis relies on imaging and biopsy to confirm the cancer and determine staging, which dictates treatment strategy. While surgical resection (e.g., the Whipple procedure) offers the only chance for cure in the minority of eligible patients, the backbone of systemic treatment involves potent chemotherapy regimens like FOLFIRINOX, with targeted therapies limited to rare subsets, such as PARP inhibitors for patients with BRCA mutations.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Pancreatic Ductal Adenocarcinoma (PDAC) – Market Access and Reimbursement Insights Report – 2025